Tóm tắt
Purpose: This study investigated the clinical and paraclinical characteristics and severity of hyperkalemia in patients with acute kidney injury (AKI) treated in the Intensive Care Unit of Hue Central Hospital, and evaluated treatment outcomes and associated factors.
Methods: A total of 121 AKI patients treated from March 2022 to June 2023 were included. Data on medical history, clinical features, laboratory findings, and hyperkalemia treatment outcomes were collected and analyzed.
Results: Hypertension was the most common comorbidity (38.8%), followed by pulmonary disease (34.7%) and diabetes (20.7%). AKI was most often detected during hospitalization (62.8%). The leading cause was sepsis/infection (90.9%), followed by nephrotoxic drugs (38.0%). Common clinical manifestations included dyspnea or tachypnea (86.0%), shock or cardiac arrest (76.0%), edema (60.3%), and fatigue (57.0%). Most patients had normal consciousness (66.9%), while 13.2% were comatose. Stage 3 AKI predominated (54.5%), with 60.3% having urine output < 0.5 ml/kg/hour. Electrocardiographic abnormalities included tachycardia or bradycardia (79.3%), ST segment depression (23.1%), flattened P waves (14.9%), and peaked T waves (13.2%). Hyperkalemia (serum potassium ≥ 5.5 mmol/L) occurred in 52.1% of patients, with severe hyperkalemia (≥ 6.5 mmol/L) in 10.7%. Mild hyperkalemia was most common (76.0%), while severe cases accounted for 21.5%. Calcium chloride was the most frequently used treatment (79.4%), followed by diuretics (63.5%), sodium bicarbonate (58.7%), and insulin with glucose infusion (57.1%). Continuous renal replacement therapy (CRRT) was applied in 19.0% of patients. Potassium levels normalized to < 5.5 mmol/L in 81.0% of patients within 6 hours and 84.1% after 6 hours. Serum potassium levels improved significantly after medical therapy or CRRT (P < 0.001). No significant associations were found between treatment outcomes and age, sex, BMI, admission characteristics, timing of detection, or hematological parameters.
Conclusions: AKI patients in the ICU commonly presented with dyspnea and shock/cardiac arrest. Hyperkalemia was frequent (52.1%), including 10.7% severe cases, but potassium levels improved significantly with appropriate treatment.
| Đã xuất bản | 30-04-2026 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Tập 16 Số 02 (2026) | |
| Phân mục | Nghiên cứu | |
| DOI | 10.34071/jmp.2026.2.1083 | |
| Từ khóa | hyperkalemia, acute kidney injury, complication |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2026 Tạp chí Y Dược Huế
Jaber S, Paugam C, Futier E, Lefrant JY, Lasocki S, Lescot T, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018 Jul 7;392(10141):31–40..
Lowe R, Ferrari M, Nasim-Mohi M. Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study. BMC Nephrol. 2021 Mar 15;22:92.
Gao XP, Zheng CF, Liao MQ. Admission serum sodium and potassium levels predict survival among critically ill patients with acute kidney injury: a cohort study. BMC Nephrol. 2019 Aug 8;20(1):311.
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1-138.
Clase CM, Carrero JJ, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2020 Jan;97(1):42–61..
Kashani K, Rosner MH, Haase M, Lewington AJP, O'Donoghue DJ, Wilson FP, et al. Quality improvement goals for acute kidney injury. Clin J Am Soc Nephrol. 2019 Jun 7;14(6):941–953.
Phạm Thị Diệu Huyền. Phân tích biến cố tăng kali máu trong sử dụng thuốc tại Bệnh viện Hữu Nghị [Luận văn Thạc sĩ Dược học]. Hà Nội: Trường Đại học Dược Hà Nội; 2018.
Poston JT, Koyner JL. Sepsis-associated acute kidney injury. BMJ. 2019;364:k4891.
Mishra RC, Sodhi K, Prakash KC, Tyagi N, Chanchalani G, Annigeri RA, et al. ISCCM guidelines on acute kidney injury and renal replacement therapy. Indian J Crit Care Med. 2022 Oct;26(Suppl 2):S13–S42..
Lê Thị Diễm Tuyết, Vũ Văn Đính. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và điều trị suy thận cấp tại khoa điều trị tích cực Bệnh viện Bạch Mai [Luận án Tiến sĩ Y học]. Hà Nội: Trường Đại học Y Hà Nội; 2010..
Hà Ngọc Diễm, Nguyễn Như Nghĩa, Phạm Văn Lình. Khảo sát tình hình tổn thương thận cấp ở bệnh nhân sốc nhiễm khuẩn tại Bệnh viện Đa khoa Trung ương Cần Thơ năm 2017–2019. Tạp chí Y Dược học Cần Thơ. 2019;19:1-7.
Green D, Green HD, New DI, Kalra PA. The clinical significance of hyperkalaemia-associated repolarization abnormalities in end-stage renal disease. Nephrol Dial Transplant. 2013 Jan;28(1):99-105.
Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990 Nov;38(5):869-872.
Mandelberg A, Krupnik Z, Houri S, Smetana S, Gilad E, Matas Z, et al. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? How safe? Chest. 1999 Mar;115(3):617–622.